このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
Axsome Therapeutics 過去の業績
過去 基準チェック /06
Axsome Therapeuticsの収益は年間平均-30.4%の割合で減少していますが、 Pharmaceuticals業界の収益は年間 減少しています。収益は年間0.4% 87.3%割合で 増加しています。
主要情報
-30.4%
収益成長率
-24.0%
EPS成長率
| Pharmaceuticals 業界 の成長 | 6.0% |
| 収益成長率 | 87.3% |
| 株主資本利益率 | -205.8% |
| ネット・マージン | -118.1% |
| 前回の決算情報 | 31 Mar 2024 |
最近の業績更新
Recent updates
Why Axsome Therapeutics Is A Promising Stock Pick In CNS Treatments
May 10Axsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 09
Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues
Apr 13Does Axsome Therapeutics (NASDAQ:AXSM) Have A Healthy Balance Sheet?
Mar 17Axsome: Unpacking Auvelity's First-Year Market Dynamics And Economic Challenges
Feb 21Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) P/S Is Still On The Mark Following 27% Share Price Bounce
Dec 27Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?
Dec 12Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?
Sep 12Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues
Aug 08Upgrade: Analysts Just Made A Dazzling Increase To Their Axsome Therapeutics, Inc. (NASDAQ:AXSM) Forecasts
May 13Earnings Update: Axsome Therapeutics, Inc. (NASDAQ:AXSM) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Mar 03Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt Sensibly?
Mar 01Is Axsome Therapeutics (NASDAQ:AXSM) Weighed On By Its Debt Load?
Nov 14Axsome Therapeutics: Clear Path Ahead For AXS07
Oct 05Axsome to resubmit marketing application for migraine therapy in Q3 2023
Sep 29Axsome: In The Middle Of Uncertainty Is Your Biggest Opportunity
Sep 16Axsome begins enrolling in late-stage study of migraine drug AXS-07
Sep 01Axsome gains 19% as FDA approves depression therapy
Aug 19Axsome Therapeutics Q2 2022 Earnings Preview
Aug 08Axsome: Breaking Bearish Trend
Jul 26Axsome: One Step At A Time
Jul 01Axsome And AXS-05: A Special Situation
May 02Axsome: A Growth Transition
Apr 13Axsome: A Speculative Buy, Undervalued Biotech With A Short-Term Catalyst
Apr 03Axsome: A Biotech With Potential Approval Of Several Drugs In Coming Years
Mar 19収支内訳
収支内訳
Axsome Therapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 31 Mar 24 | 251 | -296 | 348 | 117 |
| 31 Dec 23 | 271 | -239 | 323 | 98 |
| 30 Sep 23 | 223 | -202 | 297 | 82 |
| 30 Jun 23 | 182 | -184 | 255 | 68 |
| 31 Mar 23 | 145 | -159 | 208 | 63 |
| 31 Dec 22 | 50 | -187 | 159 | 58 |
| 30 Sep 22 | 26 | -160 | 117 | 57 |
| 30 Jun 22 | 9 | -150 | 96 | 55 |
| 31 Mar 22 | 0 | -141 | 81 | 54 |
| 31 Dec 21 | 0 | -130 | 67 | 58 |
| 30 Sep 21 | 0 | -126 | 58 | 62 |
| 30 Jun 21 | 0 | -114 | 44 | 63 |
| 31 Mar 21 | 0 | -100 | 35 | 59 |
| 31 Dec 20 | 0 | -103 | 29 | 70 |
| 30 Sep 20 | 0 | -99 | 24 | 62 |
| 30 Jun 20 | 0 | -95 | 21 | 63 |
| 31 Mar 20 | 0 | -90 | 16 | 63 |
| 31 Dec 19 | 0 | -68 | 14 | 54 |
| 30 Sep 19 | 0 | -53 | 11 | 41 |
| 30 Jun 19 | 0 | -42 | 10 | 32 |
| 31 Mar 19 | 0 | -37 | 10 | 26 |
| 31 Dec 18 | 0 | -31 | 9 | 23 |
| 30 Sep 18 | 0 | -29 | 9 | 21 |
| 30 Jun 18 | 0 | -27 | 9 | 19 |
| 31 Mar 18 | 0 | -26 | 8 | 19 |
| 31 Dec 17 | 0 | -29 | 7 | 20 |
| 30 Sep 17 | 0 | -29 | 7 | 21 |
| 30 Jun 17 | 0 | -30 | 7 | 22 |
| 31 Mar 17 | 0 | -29 | 7 | 22 |
| 31 Dec 16 | 0 | -27 | 6 | 21 |
| 30 Sep 16 | 0 | -23 | 5 | 18 |
| 30 Jun 16 | 0 | -21 | 4 | 14 |
| 31 Mar 16 | 0 | -16 | 3 | 10 |
| 31 Dec 15 | 0 | -12 | 2 | 7 |
| 30 Sep 15 | 0 | -10 | 2 | 6 |
| 30 Jun 15 | 0 | -6 | 2 | 6 |
| 31 Mar 15 | 0 | -6 | 2 | 5 |
| 31 Dec 14 | 0 | -6 | 1 | 4 |
質の高い収益: AXSMは現在利益が出ていません。
利益率の向上: AXSMは現在利益が出ていません。
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: AXSMは利益が出ておらず、過去 5 年間で損失は年間30.4%の割合で増加しています。
成長の加速: AXSMの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。
収益対業界: AXSMは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( 19.9% ) と比較することは困難です。
株主資本利益率
高いROE: AXSMは現在利益が出ていないため、自己資本利益率 ( -205.77% ) はマイナスです。